BioCentury
ARTICLE | Clinical News

FDA approves Emmaus' Endari sickle cell therapy

August 4, 2017 4:44 PM UTC

FDA approved Endari L-glutamine (NutreStore, Levoglutamide) from Emmaus Life Sciences Inc. (Torrance, Calif.) to treat sickle cell disease.

The company plans to launch Endari in 4Q17, with an anticipated list price of about $11,000-$18,000 per year...

BCIQ Company Profiles

Emmaus Life Sciences Inc.